ANTIBODIES AGAINST HUMAN IL-21 RECEPTOR AND USES THEREFOR
First Claim
Patent Images
1. An isolated antibody comprising an amino acid sequence which is at least 95% identical to an amino acid sequence chosen from SEQ ID NO:
- 1, 2, 3, 19, 20, 21, 47, 48, 49, 65, 66, 67, 83, 84, 85, 101, 102, 103, 119, 120, 121, 137, 138 and 139, wherein the antibody selectively binds to an IL-21 receptor.
0 Assignments
0 Petitions
Accused Products
Abstract
The present application provides human antibodies and antigen binding fragments thereof that specifically bind to the human interleukin-21 receptor (IL-21R). The antibodies can act as antagonists of IL-21R activity, thereby modulating immune responses in general, and those mediated by IL-21R in particular. The disclosed compositions and methods may be used for example, in diagnosing, treating or preventing inflammatory disorders, autoimmune diseases, allergies, transplant rejection, cancer, and other immune system disorders.
-
Citations
38 Claims
-
1. An isolated antibody comprising an amino acid sequence which is at least 95% identical to an amino acid sequence chosen from SEQ ID NO:
- 1, 2, 3, 19, 20, 21, 47, 48, 49, 65, 66, 67, 83, 84, 85, 101, 102, 103, 119, 120, 121, 137, 138 and 139, wherein the antibody selectively binds to an IL-21 receptor.
- View Dependent Claims (8, 9, 10, 11, 12, 13, 15, 16, 17, 18, 19, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38)
-
2. An isolated antibody encoded by a nucleotide sequence which is at least 95% identical to a nucleotide sequence chosen from SEQ ID NO:
- 10, 11, 12, 28, 29, 30, 56, 57, 58, 74, 75, 76, 92, 93, 94, 110, 111, 112, 128, 129, 130, 146, 147, and 148, wherein the antibody selectively binds to an IL-21 receptor.
-
3. An isolated antibody comprising a VH domain having an amino acid sequence which is at least 95% identical to an amino acid sequence chosen from SEQ ID NO:
- 1, 19, 47, 65, 83, 101, 119 and 137, and a VL domain having an amino acid sequence which is at least 95% identical to an amino acid sequence chosen from SEQ ID NO;
2, 20, 48, 66, 84, 102, 120 and 138, wherein the antibody selectively binds to an IL-21 receptor.
- 1, 19, 47, 65, 83, 101, 119 and 137, and a VL domain having an amino acid sequence which is at least 95% identical to an amino acid sequence chosen from SEQ ID NO;
-
4. An isolated antibody comprising a VH domain which comprises one or more CDRs chosen from SEQ ID NO:
- 4, 5, 6, 22, 23, 24;
50, 51, 52, 68, 69, 70, 86, 87, 88, 104, 105, 106, 122, 123, 124, 140, 141, 142 and conservative amino acid substitutions thereof, wherein the antibody selectively binds to an IL-21 receptor.
- 4, 5, 6, 22, 23, 24;
-
5. An isolated antibody comprising a VL domain which comprises one or more CDRs chosen from SEQ ID NO:
- 7, 8, 9, 25, 26, 27, 53, 54, 55, 71, 72, 73, 89, 90, 91, 107, 108, 109, 125, 126, 127, 143, 144, 145 and conservative amino acid substitutions thereof, wherein the antibody selectively binds to an IL-21 receptor.
-
6. An isolated antibody that competes with an antibody comprising an amino acid sequence chosen from SEQ ID NO:
- 1, 2, 3, 19, 20, 21, 47, 48, 49, 65, 66, 67, 83, 84, 85, 101, 102, 103, 119, 120, 121, 137, 138 and 139, for binding to an IL-21 receptor.
-
7. An isolated antibody which binds the same epitope on an IL-21 receptor as an antibody comprising an amino acid sequence chosen from SEQ ID NO:
- 1, 2, 3, 19, 20, 21, 47, 48, 49, 65, 66, 67, 83, 84, 85, 101, 102, 103, 119, 120, 121, 137, 138 and 139.
-
14. An isolated antibody expressed by a host cell having ATCC Deposit Designation No. PTA-5030 or PTA-5031.
- 20. A host cell having ATCC Deposit Designation No. PTA-5030 or PTA-5031.
-
22. A method of generating an antibody or antigen-binding fragment that selectively binds an IL-21 receptor comprising:
-
(a) providing a repertoire of nucleic acids encoding a variable domain that either includes a CDR 1, 2 or 3 to be replaced or lacks a CDR1, 2 or 3 encoding region; (b) combining the repertoire with a donor nucleic acid encoding an amino acid sequence substantially as set forth in SEQ ID NO;
4, 5, 6, 7, 8, 9, 22, 23, 24, 25, 26, 27, 50, 51, 52, 53, 54, 55, 68, 69, 70, 71, 72, 73, 86, 87, 88, 89, 90, 91, 104, 105, 106, 107, 108, 109, 122, 123, 124, 125, 126, 127, 140, 141, 142, 143, 144 or 145, such that the donor nucleic acid is inserted into the CDR1, 2 or 3 region in the repertoire, so as to provide a product repertoire of nucleic adds encoding a variable domain;(c) expressing the nucleic acids of said product repertoire; (d) selecting an antigen-binding fragment specific for the IL-21 receptor; and (e) recovering the antigen-binding fragment or nucleic acid encoding the antigen-binding fragment. - View Dependent Claims (23, 24)
-
Specification